RT
RT
Retatrutide is a multi-receptor agonist engineered to mimic the synergistic actions of three key metabolic hormones. By activating the GLP-1, GIP, and glucagon receptors concurrently, it is studied for its ability to enhance weight-related processes and metabolic health beyond what is typically observed with single or dual-agonist peptides. Researchers utilize this compound to explore cellular pathways governing appetite regulation, lipolysis, and insulin sensitivity in various metabolic disease frameworks.
Properties of Retatrutide
-
Peptide Sequence: Synthetic polypeptide (GLP-1/GIP/Glucagon receptor triple agonist)
-
Chemical Formula: C221H366N46O68 (approximate based on amino acid composition)
-
Molecular Mass: ~4733 g/mol
-
Vial Size: 3ml
Lyophilized Peptides
These peptides are freeze-dried without fillers to maintain purity and stability. Reconstitute with sterile solvent immediately before use in experimental protocols.
Disclaimer
This content is provided strictly for research purposes and does not constitute an endorsement or recommendation for the non-laboratory application or improper handling of peptides designed for research. The information, including discussions about specific peptides and their researched benefits, is presented for informational purposes only and must not be construed as health, clinical, or legal guidance, nor an encouragement for non-research use in humans. Peptides described here are solely for use in structured scientific study by authorized individuals. We advise consulting with research experts, medical practitioners, or legal counsel prior to any decisions about obtaining or utilizing these peptides. The expectation of responsible, ethical utilization of this information for legitimate investigative and scholarly objectives is paramount. This notice is dynamic and governs all provided content on research peptides.
Research
Retatrutide is currently a subject of intense investigation for its potential to alter metabolic markers and energy balance through the activation of multiple hormonal signaling pathways.
Metabolic and Weight-Related Modulation The triple-agonist activity of Retatrutide is designed to mimic the integrated signaling of GIP, GLP-1, and glucagon receptors. Laboratory research indicates that this multi-pathway activation may lead to increased energy expenditure and enhanced fat oxidation compared to selective agonists.¹ These effects are primary points of interest in studies focusing on obesity-related metabolic dysfunction and the regulation of lipid storage.
Glycemic Control and Insulin Sensitivity By modulating glucose-dependent insulin secretion (via GIP and GLP-1) and potentially suppressing hepatic glucose production (via glucagon receptor activity), Retatrutide is studied for its ability to stabilize blood glucose levels. Research suggests that this triple-agonist approach may improve insulin sensitivity, making it a focus for experimental models of Type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).²,³
Energy Homeostasis and Appetite Regulation Retatrutide modulates signaling in the central nervous system and peripheral tissues to influence satiety and energy intake. The integration of GIP and GLP-1 pathways is theorized to provide a more robust suppression of appetite, while glucagon receptor activation works to preserve lean mass during significant weight reduction in experimental settings.⁴,⁵
References
-
Jastreboff, A. M. et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
-
Coskun, T. et al. (2022). LY3437943, a novel triple agonist of the GIP, GLP-1 and glucagon receptors, demonstrates superior weight loss and metabolic benefits in diet-induced obese mice. Molecular Metabolism, 65, 101576. https://doi.org/10.1016/j.molmet.2022.101576
-
Urva, S. et al. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist: first-in-human study. The Lancet Diabetes & Endocrinology, 10(9), 652–663. https://doi.org/10.1016/S2213-8587(22)00177-3
-
Henderson, S. J. et al. (2020). Continued development of GIPR/GLP-1R/GCGR triple agonists for the treatment of obesity. Diabetes, Obesity and Metabolism, 22(S4), 60–68. https://doi.org/10.1111/dom.14175
-
Rosenstock, J. et al. (2023). Triple-Hormone-Receptor Agonism with Retatrutide in Type 2 Diabetes. The New England Journal of Medicine, 389(6), 527–539. https://doi.org/10.1056/NEJMoa2301971